BR0114846A - Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h - Google Patents

Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Info

Publication number
BR0114846A
BR0114846A BR0114846-0A BR0114846A BR0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A
Authority
BR
Brazil
Prior art keywords
crystals
type
nateglinide
substantially free
producing nateglinide
Prior art date
Application number
BR0114846-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR0114846A publication Critical patent/BR0114846A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0114846-0A 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h BR0114846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (1)

Publication Number Publication Date
BR0114846A true BR0114846A (pt) 2004-02-25

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114846-0A BR0114846A (pt) 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Country Status (18)

Country Link
US (2) US20030229249A1 (cg-RX-API-DMAC10.html)
EP (1) EP1334964B1 (cg-RX-API-DMAC10.html)
JP (1) JP4225057B2 (cg-RX-API-DMAC10.html)
KR (1) KR100810930B1 (cg-RX-API-DMAC10.html)
CN (1) CN100422143C (cg-RX-API-DMAC10.html)
AT (1) ATE370115T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001296001A1 (cg-RX-API-DMAC10.html)
BR (1) BR0114846A (cg-RX-API-DMAC10.html)
CA (1) CA2426745C (cg-RX-API-DMAC10.html)
CY (1) CY1106839T1 (cg-RX-API-DMAC10.html)
DE (1) DE60130014T2 (cg-RX-API-DMAC10.html)
DK (1) DK1334964T3 (cg-RX-API-DMAC10.html)
ES (1) ES2288997T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA03003575A (cg-RX-API-DMAC10.html)
PT (1) PT1334964E (cg-RX-API-DMAC10.html)
RU (1) RU2275354C2 (cg-RX-API-DMAC10.html)
TW (1) TWI293290B (cg-RX-API-DMAC10.html)
WO (1) WO2002034713A1 (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
CA2425533C (en) * 2000-10-18 2010-04-20 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
DE60129728T2 (de) * 2000-10-18 2008-04-24 Ajinomoto Co., Inc. Verfahren zur herstellung von nateglinid-kristallen
DK1334720T3 (da) * 2000-10-24 2009-01-19 Ajinomoto Kk Nateglinid-indeholdende fremstillinger
ES2321911T3 (es) * 2000-10-24 2009-06-15 Ajinomoto Kk Preparaciones farmacologicas hidrofilas que contienen nateglinida.
EP1496048A4 (en) * 2002-04-15 2006-08-02 Ajinomoto Kk NEW NATEGLINID CRYSTAL
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
WO2004009532A1 (en) * 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1535900B1 (en) * 2003-11-26 2006-12-27 A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. Process for the preparation of nateglinide, preferably in b-form
CA2563793A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
WO2011157986A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
JP2015521174A (ja) * 2012-05-08 2015-07-27 セリックスビオ プライヴェート リミテッド 糖尿病の治療のための組成物および方法
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DK0526171T3 (da) 1991-07-30 1997-08-25 Ajinomoto Kk Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
HK1049622A1 (en) * 1999-12-28 2003-05-23 Ajinomoto Co., Inc. Oral preparations for diabetes
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
DE60129728T2 (de) * 2000-10-18 2008-04-24 Ajinomoto Co., Inc. Verfahren zur herstellung von nateglinid-kristallen
CA2425533C (en) * 2000-10-18 2010-04-20 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
DK1334720T3 (da) * 2000-10-24 2009-01-19 Ajinomoto Kk Nateglinid-indeholdende fremstillinger
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
JPWO2002034713A1 (ja) 2004-03-04
CY1106839T1 (el) 2012-05-23
EP1334964B1 (en) 2007-08-15
RU2275354C2 (ru) 2006-04-27
US7544834B2 (en) 2009-06-09
ATE370115T1 (de) 2007-09-15
DK1334964T3 (da) 2007-09-24
US20030229249A1 (en) 2003-12-11
EP1334964A1 (en) 2003-08-13
ES2288997T3 (es) 2008-02-01
CN100422143C (zh) 2008-10-01
MXPA03003575A (es) 2003-07-14
TWI293290B (cg-RX-API-DMAC10.html) 2008-02-11
US20070232829A1 (en) 2007-10-04
CA2426745C (en) 2009-09-15
KR20030059212A (ko) 2003-07-07
JP4225057B2 (ja) 2009-02-18
CN1483018A (zh) 2004-03-17
WO2002034713A1 (en) 2002-05-02
CA2426745A1 (en) 2003-04-23
AU2001296001A1 (en) 2002-05-06
PT1334964E (pt) 2007-09-20
DE60130014D1 (de) 2007-09-27
DE60130014T2 (de) 2008-05-08
EP1334964A4 (en) 2005-09-28
KR100810930B1 (ko) 2008-03-10

Similar Documents

Publication Publication Date Title
BR0114846A (pt) Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
BR0008050A (pt) Processo e dispositivo para filtração emcontracorrente
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
BR9711861A (pt) Processo para a fabrica-Æo de uma composi-Æo detergente por um processo sem a utiliza-Æo de torre
PT1144368E (pt) Sulfonamidas acetilenicas de acidos hidroxamicos baseados em alfa-aminoacidos como inibidores de tace
BR0005488A (pt) Processo para a preparação de carbonato de vinileno, e o uso do mesmo
BR0303196A (pt) Suporte de montagem de uma extremidade frontal de um veìculo automotor e processo para a fixação destacável de um módulo de refrigeração em um suporte de montagem de uma extremidade frontal
CO5200765A1 (es) Nuevos androgenos oralmente activos que son derivados de delta 14 nandrolona 7 alfa - sustituidos
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
DE50101929D1 (de) Dermales applikationssystem für aminolävulinsäure
AR048279A1 (es) La forma ii cristalina de cabergolina
BR9915714A (pt) Remoção de silicatos dissolvidos de solventes da sìntese direta de álcool-silìcio
EP1636176A4 (en) POLYMORPHIC FORM A OF 4 -6-ACETYL-3-¬3- (4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO) PROPOXY-2-PROPYLPHENOXY BUTTERIC ACID
BR0108912A (pt) Processamento de material por expansão-contração de solvente repetido
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro
BR9916382A (pt) Processo para a preparação de um composto
BR0205164A (pt) Processo para purificar azeotropicamente material orgânico polimerizável aquoso
BR9909029A (pt) Estabilização de poliisocianatos orgânicos
BR0112820A (pt) Processo para a preparação de (alfa) clorocetonas
ATE423106T1 (de) Verfahren zur kristallisation von n-(1(s)- ethoxycarbonyl-3-phenylpropyl)-l-alanin n- carbonsäureanhydrid
AR034084A1 (es) Proceso para la remocion de dimetil eter en la sintesis de sevoflurano.
BR0112911A (pt) Reciclagem de fluxos
BR9914826A (pt) Processo de cristalização de cristais de éster metìlico de n- [n-(3,3-dimetilbutil)-l-alfa-aspartil] -l-fenilalanina
RU2003133471A (ru) Выращенный монокристалл фторида кальция

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2274 DE 05/08/2014

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.